Speakers:
Brian Weiss, CEO, Carebox
Leah Szumita, Senior Director, Clinical Trial Support Center, Blood Cancer United
Key Takeaways
• Each Blood Cancer United enrolment took at least 22 nurse calls and emails after matching.
• Most blood cancer patients seeking trial help are relapsed or refractory and want their next option.
• Per-study pre-screeners repeat roughly 80% of the same content, each needing separate IRB approval.
• Patient-facing digital tools let patients explore at their own pace; the balance with nurse navigation depends on the trial, budget and commercial setting.
• Ask what data sits beneath any AI recruitment tool before judging its features.
Behind every clinical trial enrolment that Blood Cancer United’s nurse navigators help achieve sit at least 22 phone calls and emails made on the patient’s behalf, most of them after a suitable trial has already been found. Leah Szumita, who runs the organisation’s Clinical Trial Support Center, treats each one as a point where a patient could be lost: “To me, those are like 22 cracks in the road that unfortunately many patients might fall through if they tried to navigate this on their own.”
Szumita, senior director of the centre at Blood Cancer United, formerly the Leukemia and Lymphoma Society, co-presented the session at Pharma Clinical Innovation USA 2026 in Philadelphia with Brian Weiss, chief executive and founder of Carebox, which supported the session and has worked with Blood Cancer United since 2019. Weiss used her account to press a wider case. Sponsors organise recruitment around one protocol at a time, he said, while patients look for a sequence of treatment options, and the mismatch costs sponsors both patients and the data that would explain why they were lost.
Most enrolment work comes after the match
The numbers Szumita gave are self-reported and striking. In the last fiscal year the centre worked with just over 1,200 patients, and its enrolment rate for eligible patients was 24 per cent, which she described as “much higher than the national average for adult cancer clinical trial enrolment”. The 22 interactions per enrolment were, in her words, “those phone calls and emails that I mentioned”: outreach to sites about eligibility, questions about new patient appointments and wait lists, insurance queries and the search for travel support for patients and caregivers.
That follow-through rests on continuity. Every patient or family member is paired with one designated nurse navigator for the whole relationship, which can last a few weeks but often runs for months or years. “It is so rare to have a free nurse at your disposal by phone or email 24/7,” Szumita observed, calling it the service’s “secret sauce”.
The nurses, all specialists in paediatric or adult blood cancer, begin with an assessment that goes well beyond diagnosis, markers and mutations. They establish what the patient understands about the options available, what they prefer, what their goals of care are and what psychosocial support would make taking part in a trial feasible. Matching follows, combining the platform’s results with the nurse’s clinical judgement.
The output is deliberately short. “But what we don’t do is provide patients with a 20-page list of clinical trials,” Szumita explained. Patients receive a usable shortlist and are told to take it to their provider or a second opinion for medical advice. Asked from the floor how the team handles molecular profiling, which she called increasingly prevalent, she was clear about the boundary: her nurses are not genetic counsellors, but they help patients understand their reports and prepare questions for their next appointment.
She positioned the whole service alongside treating physicians rather than in competition with them. “We know that providers don’t have the resources to do this, particularly in the community setting. So we want to be an extension of those providers.” Her nurses take on the assessment and compile the trial list, then encourage a shared decision-making conversation between doctor and patient and stay in the background for further help. Blood Cancer United is working to extend that reach among healthcare providers.
For a clinical operations leader, this relocates the recruitment problem. A plan that measures impressions, referrals and matches stops counting at the point where, on Szumita’s figures, most of the work begins. The question worth putting to any recruitment plan is who will make those 22 contacts for a patient who has no navigator, and whether the community sites a study depends on have anyone to make them.
Patients look for options not studies
Weiss framed the structural problem before Szumita spoke. “Patient recruitment is overwhelmingly one study at a time,” he argued, whether a trial is in rescue mode or on schedule. The sponsor builds outreach, a website, a call centre for secondary screening and a referral process with sites, all around a single protocol. “The patient’s journey is not about that. It’s about treatment options at different points along the way.”
Szumita’s caseload illustrated the point. Some patients arrive newly diagnosed and want every option, trials included. Others are on watch and wait and want a backup plan should they need active treatment. “The majority of our patients do come to us in a relapsed or refractory state. So they really want to know what their next option is.” Many return to the same nurse months or years later when they need help again.
Weiss carried that logic into registries. Carebox, he stressed, owns none; its advocacy group and pharma customers own their own, and the registries shared across the advocacy community can also be used by smaller studies. Their value, in his account, lies in time. “You may be focused right now on recruiting for this trial right now, but the patient is thinking, what is next now?” A patient who does not fit today’s study may fit one after the next scan or once watch and wait ends.
The scale of the portfolio does not change the point, in Weiss’s view. A research centre such as UCLA Health may run hundreds of trials and a large sponsor 50 or 100, yet even a biopharma company with one or two studies, he maintained, should still be able to draw on the wider view that an advocacy network provides. The elements of recruitment stay the same: promotion, pre-qualification, referral, navigation and measurement. What changes is the mindset behind them.
Blood Cancer United had to learn a version of this itself. Szumita acknowledged that the organisation’s preference for keeping trial information internal and asking patients to come to its nurses first “was really becoming antiquated”. In her words, “we were a little bit slow to come to this acceptance, but we knew patients need information quickly.” Some patients want to explore at their own pace before speaking to anyone, so the organisation added a patient-facing version of Carebox Connect. Weiss described the digital experience as working “not as a substitute, but as a feeder into that process”, and conceded that every organisation will strike its own balance between digital and concierge support, depending on budget and commercial setting.
For sponsors, the implication is uncomfortable. A patient screened out of one study is not a failed lead. On Szumita’s evidence, that patient is likely to be looking for the next option within months, and a recruitment model that closes its books when the study fills discards them.
Retire the per-study pre-screener
Weiss’s sharpest proposal concerned screening. “I hope in a few years from now the notion of a per-study pre-screener will be dead,” he told the room, objecting to “reinventing this wheel over and over again, IRB approving each individual one when 80% is the same”. Each new questionnaire needs its own institutional review board (IRB) approval, and each asks patients many of the same questions again.
His alternative is condition matching built on dynamic questions, which, he argued, can present patients with several trial options now and in future without repeated questionnaires, while keeping the specificity and quality of referral that sponsors need. The same tool is the basis of the matching Szumita’s nurses use.
The stronger argument is about what a shared approach reveals. Once a new study is coded against a common matching system, Weiss explained, a sponsor can see where matching patients are located and, for those who do not match, why not, by category such as comorbidity, previous treatment or biomarker. It can also show why patients who were matched still fail to screen, including the patient-reported barriers raised earlier in the day, such as distance and physician recommendation, rather than inclusion and exclusion criteria alone. With a pre-screener built for one study, he cautioned, that information “just goes away” when the study ends.
For a trial design or feasibility leader, this is the more practical case. Disqualification reasons gathered across many studies are evidence about eligibility criteria, and evidence about criteria is what protocol teams most often lack when they set them. A sponsor that commissions a new pre-screener for every study pays repeatedly for questions it has already asked and keeps none of the answers.
Recruitment AI depends on cross-trial data
Weiss extended the same argument to artificial intelligence (AI). Sponsors will be offered AI tools that sit on top of recruitment analytics, suggesting trends, root causes and site performance insights, and the question he urged them to ask is what data lies underneath. “If it’s just about this one study, from clicks and impressions through the funnel, that’s a very limited view.” A portfolio view over time, across advocacy groups, vendors and therapeutic areas, would be far broader. Only then, he argued, does it make sense to discuss what AI can add: “the quality of the data has to be there first.”
Szumita’s history offers a smaller version of the same lesson. When the partnership began seven years ago, her team’s process was entirely manual. “It would take upwards of probably 8 to 10 hours for us to be able to go from that assessment conversation to actually providing the patient with useful information.” What changed, she recalled, was a partner that “understood the value of incorporating technology without losing the human component of what we were doing”. The technology made her nurses faster; it did not replace the 22 contacts.
Weiss closed with questions for sponsors: whether they are meeting patients where they are, whether their recruitment approach follows the patient journey, and whether their platform does more than list studies. “If it’s just a lightly touched-up version of ClinicalTrials.gov, it’s not doing the things that we’re talking about here.” He was candid about his own company’s place in the picture. “Doesn’t mean we have all the answers. We don’t. There are a lot of really tough challenges here and we’re just one piece of the puzzle.”
The session’s evidence points to a clear conclusion. Sponsors measure recruitment by the study, and that unit hides the two things that most determine whether a patient enrols: the follow-through after a match and the reasons patients fall away. Szumita’s 22 contacts show where the effort sits; Weiss’s disqualification data shows what is lost when each study starts from zero. A clinical leader who wants better recruitment should ask of every programme and every vendor what happens to the screening data, and to the patients who did not qualify, on the day the study closes.
In order to get you the highlights of Pharma Clinical Innovation USA 2026 faster, we are using generative AI technology to summarize the transcripts of the sessions. If you have any feedback about the summary, please contact lucy.fisher@thomsonreuters.com.